A new COVID-19 subvariant, NB.1.8.1, has caused a surge in emergency room visits and hospitalizations in China, Hong Kong, and Taiwan—and has now been detected in the U.S., according to a detailed report from Forbes. While global public health systems scramble to respond, experts warn that the U.S. remains vulnerable due to limited surveillance and shifting federal policies.
NB.1.8.1 is part of the ever-evolving lineage of SARS-CoV-2 subvariants. In recent months, it has quickly overtaken other strains across East Asia, raising concerns over its potential to spread worldwide. According to Forbes, the variant now accounts for up to 30% of sequenced COVID-19 cases in several countries, particularly in Hong Kong where health authorities have renewed mask guidance for crowded public spaces.
New COVID Variant Detected Across Multiple U.S. States
The Centers for Disease Control and Prevention (CDC) has already flagged NB.1.8.1 through its airport surveillance program, with international travelers arriving in California, Washington, Virginia, and New York testing positive for the strain. Cases have also been confirmed in Ohio, Rhode Island, and Hawaii.
But as Forbes points out, the U.S. lacks a consistent national genomic surveillance system. Detection often depends on individuals choosing to test at labs capable of sequencing viral samples—an increasingly rare chain of events as federal support for COVID infrastructure wanes.
See also: Trump Orders U.S. Embassies to Stop Student Visa Interviews in Sudden Crackdown
What Makes NB.1.8.1 Different?
Early data suggests NB.1.8.1 may have a stronger ability to bind to human cells than some other variants, making it potentially more transmissible. However, there’s no current evidence that it causes more severe illness.
The variant is currently competing with another emerging strain, XFG, which appears to evade immune protection more effectively. Which of the two comes to dominate globally may depend on factors like regional vaccination rates, prior exposure, and existing immunity profiles.
Vaccine Efficacy and Future Protection
NB.1.8.1 is genetically closer to LP.8.1, the variant targeted by updated vaccines released in late 2024. While current shots may still offer some protection, vaccine developers are weighing updates to better address the newer variants. That decision could influence the level of community immunity in the coming months.
The FDA, meanwhile, is reportedly considering scaling back vaccine approvals to only those over age 65 or with chronic conditions—raising questions about preparedness for another wave of infections.
See also: Trump Administration Just Limited Access to COVID Vaccines—Do You Still Qualify?
No National Strategy, Still
Five years into the pandemic, the U.S. still lacks a long-term COVID response plan. Public messaging has become politicized, mask mandates remain taboo, and federal agencies like the CDC and NIH have seen budget and personnel cuts under the current administration.
While NB.1.8.1 is not currently associated with increased mortality, it’s a reminder that SARS-CoV-2 continues to evolve—and the tools needed to track and respond to new threats may not be where they need to be.
